A Controlled, Randomized-Blinded Clinical Trial to Assess the Efficacy of a Nitric Oxide Releasing Patch in the Treatment of Cutaneous Leishmaniasis by Leishmania (V.) panamensis

Abstract

Abstract. A topical nanofiber nitric oxide (NO) releasing patch (»3.5 μmol NO/cm

Leishmanicidal Activities of Novel Synthetic Furoxan and Benzofuroxan Derivatives

“…Moreover, S-nitrosoglutathione demonstrated activity against intracellular amastigotes and showed a healing effect on localized cutaneous leishmaniasis lesions caused by L. major and L. braziliensis in mice (49). Topical treatment of cutaneous leishmaniasis lesions by NO donors seems to improve healing and reduce the number of parasites; however, this beneficial effect is directly related to the chemical stability of the NO donor compound (49,50).…”

“…Compound 14b has demonstrated activity comparable to that of amphotericin B. Cytotoxicity studies using murine macrophages have demonstrated that the intermediate compounds (3, 13a and -b, and 7) were not selective for the parasite, and the SI 1 ranged from 0.38 to 3.61. The selectivity index 1 (SI 1 ) represents the ratio between CC 50 and IC 50 for promastigotes. The compounds 8a and 14a to -e were more selective for the parasite than for mammalian cells (SIs ranging from 7.5 to 38.6).…”

In Pursuit of Functional Electrospun Materials for Clinical Applications in Humans

“…A transdermal patch comprised four layers of electrospun polyurethane fibers and designed to release nitric oxide (NO) delivered as bound nitrite on polysulfonate beads has been evaluated in two different Phase III, doubleblind clinical trials [17][18][19]. In a study for treatment of cutaneous leishmaniasis ulcers (NCT00317629), topical daily application of the NO patch for 20 days did not have sufficient efficacy compared with a standard treatment and the study was terminated [19]. A separate study of the same materials for treating diabetic foot ulcers is still pending [17].…”

“…For example, SURGICLOT ® developed by St. Teresa Medical, Inc. ® (NCT02509208) is being evaluated as a hemostatic dressing that uses electrospun dextran fibers to deliver 10 In pursuit of functional electrospun materials for clinical applications Review thrombin and fibrinogen proteins to promote blood clotting at a surgical or wound site [15,16]. A transdermal patch comprised four layers of electrospun polyurethane fibers and designed to release nitric oxide (NO) delivered as bound nitrite on polysulfonate beads has been evaluated in two different Phase III, doubleblind clinical trials [17][18][19]. In a study for treatment of cutaneous leishmaniasis ulcers (NCT00317629), topical daily application of the NO patch for 20 days did not have sufficient efficacy compared with a standard treatment and the study was terminated [19].…”

Air plasma-generated nitric oxide in treatment of skin scars and articular musculoskeletal disorders: Preliminary review of observations

“…Nitric oxide is also a very effective agent against fungi [13][14][15][16] and parasites (Leshmaniasis) [17][18]. A main benefit of gNO biodecontamination is its ability to treat a wide range of pathogens rather than a specific pathogen.…”